Research Topics
| Gary LichtensteinSummaryAffiliation: University of Pennsylvania Country: USA Publications
| Collaborators
|
Detail Information
Publications
Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registryGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Am J Gastroenterol 107:1409-22. 2012..The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD)...- A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel diseaseGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Am J Gastroenterol 107:1051-63. 2012..The objective of this study was to analyze the safety of long-term infliximab treatment, with/without concomitant immunomodulators, across Crohn's disease (CD) and ulcerative colitis (UC) clinical trials... 
Review article: Bowel preparation for colonoscopy--the importance of adequate hydrationG R Lichtenstein
Hospital of the University of Pennsylvania, Gastroenterology Division, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 26:633-41. 2007..Addressing dehydration-related safety issues through patient screening and education may improve acceptance of bowel preparations, promote compliance and increase the likelihood of a successful procedure...- Current and Future Anti-TNF Therapy for Inflammatory Bowel DiseaseMark T Osterman
Gary R Lichtenstein, MD Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Curr Treat Options Gastroenterol 10:195-207. 2007..The future of anti-TNF therapy in inflammatory bowel disease is very bright, as exciting new developments continue to be made at a rapid pace... - Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitisGary R Lichtenstein
Center for Inflammatory Bowel Disease, University of Pennsylvania Health System, Philadelphia, PA, USA
J Clin Gastroenterol 40:669-77. 2006..Thus, despite the availability of ileal J-pouch-anal anastomosis, surgery does not always restore all aspects of QOL to normal... - Prevention and treatment of osteoporosis in inflammatory bowel diseaseGary R Lichtenstein
University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104 4283, USA
Inflamm Bowel Dis 12:797-813. 2006..They should not be interpreted as quality standards... - Safety of biologics in inflammatory bowel diseaseWojciech Blonski
Center for Inflammatory Bowel Diseases, Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Curr Treat Options Gastroenterol 9:221-33. 2006..Moreover, postmarketing experience also provides very valuable information about any side effects occurring during treatment with this agent... - Serious infections and mortality in association with therapies for Crohn's disease: TREAT registryGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Clin Gastroenterol Hepatol 4:621-30. 2006..Long-term safety data for infliximab and other therapies in Crohn's disease (CD) are needed... - Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's diseaseGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Gastroenterology 128:862-9. 2005..We examined the effect of infliximab maintenance treatment on hospitalizations, surgeries, and procedures in patients with fistulizing Crohn's disease enrolled in the ACCENT II study... - Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapyGary R Lichtenstein
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Gastroenterology 127:1558-64. 2004 - Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparationG R Lichtenstein
University of Pennsylvania, Gastroenterology Division, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 26:1361-70. 2007..Aim To compare patient acceptance, preference and tolerability of 32-sodium phosphate tablets vs. 2L polyethylene glycol solution plus 4 bisacodyl tablets for bowel preparation... 
Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysisG R Lichtenstein
Gastroenterology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 29:643-53. 2009..Aim To evaluate budesonide's safety profile in CD patients, in particular, incidences of clinically important AEs known to be associated with systemic GCSs...- Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysisG R Lichtenstein
Gastroenterology Division, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104 4283, USA
Aliment Pharmacol Ther 33:672-8. 2011..Recent studies have focused on the importance of mucosal healing in ulcerative colitis (UC). However, it was still unclear whether higher doses of delayed-release mesalazine (mesalamine) could provide additional benefit... - Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trialsG R Lichtenstein
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Aliment Pharmacol Ther 30:210-26. 2009..Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated... - Bowel preparations for colonoscopy: a reviewGary Lichtenstein
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Am J Health Syst Pharm 66:27-37. 2009..The mechanisms of action, clinical efficacy, tolerability, and safety of two major classes of bowel purgatives, poly-ethylene glycol- electrolyte lavage solutions (PEG-ELSs) and sodium phosphate preparations, are reviewed... - Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patientsFaten N Aberra
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Gastroenterology 125:320-7. 2003..6-Mercaptopurine/azathioprine alone and the addition of 6-mercaptopurine/azathioprine for patients receiving corticosteroids was not found to significantly increase the risk of postoperative infectious complications... - Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisGary R Lichtenstein
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Clin Gastroenterol Hepatol 5:95-102. 2007..We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis... - Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitisMical S Campbell
Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Liver Int 25:311-6. 2005..Perhaps other known risk factors for osteoporosis will be important predictors of abnormal bone density in this patient population... - Infliximab in fistulizing Crohn's diseaseMark T Osterman
Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
Gastroenterol Clin North Am 35:795-820. 2006..Proper fistula management also relies heavily on accurate diagnosis, especially defining the anatomy of the fistula, ascertaining whether abscess formation is present, and determining the location and extent of intestinal inflammation... - Complications of biological therapy for inflammatory bowel diseasesWojciech Blonski
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Curr Opin Gastroenterol 22:30-43. 2006..In the case of the remaining agents the data concerning safety in inflammatory bowel disease are limited, as these agents were not evaluated in as many trials as infliximab; indeed, some of them included only several patients... - Recent developments in inflammatory bowel diseaseChinyu Su
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Third Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
Med Clin North Am 86:1497-523. 2002.... - What is the optimal therapy for Crohn's disease: step-up or top-down?Ming Valerie Lin
Department of Internal Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, USA
Expert Rev Gastroenterol Hepatol 4:167-80. 2010..Future clinical trials will be crucial in answering these questions... - Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel diseaseJohn T Chang
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA
Nat Clin Pract Gastroenterol Hepatol 3:220-8. 2006..This review provides insights into the use of antagonists of tumor-necrosis factor-alpha for the treatment of inflammatory bowel disease... - Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance ratesMark T Osterman
Division of Gastroenterology, Department of Medicine, Penn Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Methods Find Exp Clin Pharmacol 31:41-6. 2009..This review article summarizes the data on the use of both conventional aminosalicylates and MMX mesalamine in the treatment of ulcerative colitis... - Infliximab in ulcerative colitisFaten N Aberra
Division of Gastroenterology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
Gastroenterol Clin North Am 35:821-36. 2006.... - Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeriesGary R Lichtenstein
Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, Pennsylvania 19104-4283, USA
Am J Gastroenterol 99:91-6. 2004..CONCLUSIONS: CDAI remission is associated with reduced hospitalizations and surgeries, increased employment, and normalized quality of life. Sustained CDAI remission should be the key therapeutic goal in managing Crohn's disease... - Infliximab improves quality of life in patients with Crohn's diseaseGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
Inflamm Bowel Dis 8:237-43. 2002..The aim of this study was to assess the effect of infliximab on quality of life in patients with active Crohn's disease (CD) inadequately responsive to concomitant therapies... - The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's diseaseMichael Pazianas
Department of Medicine, University of Pennsylvania, 3615 Chestnut Street, Philadelphia, PA 19104, USA
Ann N Y Acad Sci 1068:543-56. 2006.... - An evidence-based approach to studies of the natural history of gastrointestinal diseases: recurrence of symptomatic Crohn's disease after surgeryJames D Lewis
Department of Medicine, and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA
Clin Gastroenterol Hepatol 1:229-36. 2003 - Seasonal variation in flares of inflammatory bowel diseaseJames D Lewis
Center for Clinical Epidemiology and Biostatistics and Department of Medicine, University of Pennsylvania Centers for Education and Research on Therapeutics, Philadelphia, 19104 6021, USA
Gastroenterology 126:665-73. 2004..The purpose of this study was to determine whether relapse of inflammatory bowel disease follows a seasonal pattern either across a cohort of patients or within individual patients... - Chemoprevention: risk reduction with medical therapy of inflammatory bowel diseaseErick P Chan
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA
Gastroenterol Clin North Am 35:675-712. 2006..Further studies, including prospective trials when possible and cost-effectiveness analyses, need to be performed to develop an optimal strategy for the reduction of cancer risk in patients with IBD... - [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease]Gary R Lichtenstein
Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Rev Gastroenterol Mex 71:351-401. 2006 - A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitisChinyu Su
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania and University of Pennsylvania Presbyterian Medical Center, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
Gastroenterology 132:516-26. 2007..The aims of this study were to estimate the placebo rates of remission and response in placebo-controlled, randomized clinical trials for active UC and to identify factors influencing these rates... - Evaluation of bone mineral density in patients with inflammatory bowel diseaseCarmen Cuffari
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor, Radvin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
Curr Gastroenterol Rep 5:261-2. 2003 - A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopyJeff E Mandel
Department of Anesthesiology and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Anesth Analg 106:434-9, table of contents. 2008..We hypothesized that, by using remifentanil in conjunction with propofol and using PCS in both arms of the study, we could demonstrate marked improvements in facility use compared with fentanyl plus midazolam... - Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trialJames D Lewis
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Gastroenterology 134:688-95. 2008..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)... - Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitisJames D Lewis
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6021, USA
Inflamm Bowel Dis 14:1660-6. 2008..We sought to assess what constitutes a clinically meaningful change in these indices using data from a recently completed placebo-controlled clinical trial... - Management of Crohn's disease in adultsGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Am J Gastroenterol 104:465-83; quiz 464, 484. 2009..The final recommendations are based on the data available at the time of the production of the document and may be updated with pertinent scientific developments at a later time... - Treatment of fistulizing Crohn's diseaseThomas A Judge
Gastroenterology Division, Robert Wood Johnson Medical School, Cooper University Hospital, University of Medicine and Dentistry of New Jersey, 401 Hadden Avenue, Room 374, Camden, NJ 08103, USA
Gastroenterol Clin North Am 33:421-54, xi-xii. 2004..The appropriate approach to asymptomatic patients is uncertain because there are little data to indicate if treatment alters the natural course of disease... - Importance of mucosal healing in ulcerative colitisGary R Lichtenstein
Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 4283, USA
Inflamm Bowel Dis 16:338-46. 2010..This review evaluates the effect of medical therapy on mucosal healing in patients with UC and explores the importance of this outcome measure, both from the patient's perspective and clinical trial experience. Inflamm Bowel Dis 2009... - Efficacy and safety of adalimumab in Crohn's diseaseGary R Lichtenstein
University of Pennsylvania School of Medicine Hospital of the University of Pennsylvania, 3rd Floor Ravdin Building 3400 Spruce Street Philadelphia, PA, USA
Therap Adv Gastroenterol 1:43-50. 2008..Based on robust short- and long-term efficacy data from large randomized controlled trials and a favorable safety signal, ADA has become a key addition to the therapeutic armamentarium in the treatment of moderate-to-severe CD... - A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's diseaseChinyu Su
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, UPenn Medical Center Presbyterian, 218 Wright Saunders Building, 39th and Market Streets, Philadelphia, PA 19104, USA
Gastroenterology 126:1257-69. 2004..The aims of this study were to estimate rates of remission and response in patients with active CD receiving placebo and to identify factors influencing these rates... - Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurineChinyu Su
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA
Gastroenterol Clin North Am 33:209-34, viii. 2004..Emerging literature on the potential application of pharmacogenetic testing and metabolite monitoring are also discussed... - Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapyGary R Lichtenstein
Department of Medicine, Hospital of the University of Pennsylvania, School of Medicine, PA, USA
Am J Gastroenterol 100:1433-5. 2005 - Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's diseaseGary R Lichtenstein
University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Inflamm Bowel Dis 10:S2-10. 2004..Here we also evaluate the current preferable treatment practices, based on scientifically valid research and collective clinical experience, for the management of mild to moderate Crohn's disease... - Antibiotic use and the risk of flare of inflammatory bowel diseaseFaten N Aberra
Division of Gastroenterolgy, University of Pennsylvania School of Medicine, Philadephia, 19104, USA
Clin Gastroenterol Hepatol 3:459-65. 2005..Intestinal microbial flora participate in the pathogenesis of inflammatory bowel disease. Because antibiotic therapy alters intestinal microbial flora, we hypothesized that use of antibiotics might decrease the risk of flare... - Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 monthsGary R Lichtenstein
Gastrointestinal Division, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Clin Gastroenterol Hepatol 8:600-9. 2010..We assessed the long-term efficacy, safety, and immunogenicity of continuous versus interrupted maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease... - Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease expertsGary R Lichtenstein
University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Inflamm Bowel Dis 10:S11-21. 2004 - Infliximab use in Crohn's diseaseMeenakshi Bewtra
University of Pennsylvania Health System, 100 Centrex, IMR, 3400 Spruce Street, Philadelphia, PA 19104, USA
Expert Opin Biol Ther 5:589-99. 2005..The clinical efficacy, indications, safety profile and future of infliximab are reviewed... - Methods to avoid infections in patients with inflammatory bowel diseaseFaten N Aberra
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Inflamm Bowel Dis 11:685-95. 2005..Recommendations are also provided for prevention of infection... - Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitisGary R Lichtenstein
Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Dig Dis Sci 53:175-80. 2008..22). No severe adverse events were observed. This trial suggests a potential benefit over placebo for both achieving clinical response and induction of remission in patients with active ulcerative colitis without apparent toxicity... - Risk for active tuberculosis in inflammatory bowel disease patientsFaten N Aberra
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Clin Gastroenterol Hepatol 5:1070-5. 2007..The primary aim of this study was to determine the incidence of active tuberculosis in an inflammatory bowel disease population compared with the general population before the availability of infliximab... - Evaluation of polypoid lesions in inflammatory bowel diseaseAshish Chawla
Center for Inflammatory Bowel Disease, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Department of Medicine, Division of Gastroenterology, 3400 Spruce Street, Ravdin Building, Philadelphia, PA 19104-4283, USA
Gastrointest Endosc Clin N Am 12:525-34, ix. 2002..The patients who have indeterminate lesions can be differentiated based on the endoscopic, histologic, and molecular features of the lesion. Long-term follow-up is necessary to determine the natural history of these lesions... - Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitisGary R Lichtenstein
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
Rev Gastroenterol Disord 8:21-30; quiz 31-2. 2008..Novel formulations of mesalamine and newly devised, high-dose regimens offer additional therapeutic options and may lead to improved treatment adherence, longer-lasting periods of remission, and enhanced patient well-being... - Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's diseaseGary R Lichtenstein
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283, USA
Am J Gastroenterol 101:1030-8. 2006.... - Evaluation of bone mineral density in inflammatory bowel disease: current safety focusGary R Lichtenstein
Center for Inflammatory Bowel Diseases, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Am J Gastroenterol 98:S24-30. 2003..This review discusses the pathophysiology involved in the formation of abnormal bone mineral density and the treatment of this condition in patients with inflammatory bowel disease... - Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritisJeffry A Katz
Division of Gastroenterology, Case Western Reserve University, Cleveland, Ohio 44106-5066, USA
Am J Gastroenterol 99:2385-92. 2004..No increased risk of adverse outcome was detected, however, follow-up of larger numbers of pregnant women exposed to infliximab will be necessary to definitively exclude any fetal risk... - The impact of increased body mass index on the clinical course of Crohn's diseaseDavid J Hass
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283, USA
Clin Gastroenterol Hepatol 4:482-8. 2006..5 kg/m2. This suggests that overweight CD patients require earlier surgical intervention and perhaps more aggressive medical therapy... - Crohn's disease in the ileal pouch after total colectomy for ulcerative colitis: findings on pouch enemas in six patientsNicolaus A Wagner-Bartak
Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
AJR Am J Roentgenol 184:1843-7. 2005.... - Reduction of colorectal cancer risk in patients with Crohn's diseaseGary R Lichtenstein
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Rev Gastroenterol Disord 2:S16-24. 2002..This article reviews the current literature relating to the risk of cancer for patients with IBD and methods available to help reduce this risk... - A prospective, randomized, comparative trial evaluating respiratory depression during patient-controlled versus anesthesiologist-administered propofol-remifentanil sedation for elective colonoscopyJeff E Mandel
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Gastrointest Endosc 72:112-7. 2010..Patient-controlled sedation (PCS) with propofol-remifentanil (PR) is associated with rapid sedation and recovery, but it is associated with a greater requirement for airway rescue than PCS with midazolam-fentanyl... - Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitisChinyu Su
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
Am J Gastroenterol 97:2577-84. 2002..Individuals who are refractory to corticosteroids, however, may be unlikely to respond to infliximab. A randomized controlled trial is necessary to further investigate the efficacy of infliximab in patients with UC... - Are there predictors of Remicade treatment success or failure?Chinyu Su
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
Adv Drug Deliv Rev 57:237-45. 2005..Data from the literature in these areas are reviewed in this article, pointing to the need for additional research in this topic... - High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitisWojciech Blonski
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, USA
Scand J Gastroenterol 43:817-20. 2008..We hypothesize that colectomy is not warranted in patients who undergo complete excision of adenoma-like DALMs with HGD in UC... - Corticosteroids in Crohn's diseaseYu-Xiao Yang
Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia 19104-4283, USA
Am J Gastroenterol 97:803-23. 2002..Alternative classes of medical therapy for Crohn's disease, including modified corticosteroids and a group of new biological therapies, have proven to be efficacious in the management of active and/or quiescent Crohn's disease... - Medical therapy of inflammatory bowel diseaseGary R Lichtenstein
Gastroenterology Division, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, University of Pennsylvania Health System, Philadelphia, PA 19104-4283, USA
Gastroenterol Clin North Am 33:xv-xvi. 2004 - Colonic dysplasia and cancer in inflammatory bowel diseaseThomas A Judge
Division of Gastroenterology, Department of Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, 3rd Floor Ravdin Building, Philadelphia, PA 19104-4283, USA
Gastrointest Endosc Clin N Am 12:495-523. 2002..Efforts to develop chemopreventative agents and improved surveillance methods remain areas of active investigation... - Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis?Wojciech Blonski
Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4283, USA
Scand J Gastroenterol 43:698-703. 2008..The aim of this study was to determine whether dysplasia is visible during routine surveillance colonoscopy by evaluating only patients who had dysplasia without overt carcinoma... - Recent developments in the pharmacological treatment of Crohn's diseaseRadhika Srinivasan
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
Expert Opin Investig Drugs 13:373-91. 2004..The future for CD patients is promising with the ever-expanding repertoire of drugs that are being studied... - Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysisMark T Osterman
Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Gastroenterology 130:1047-53. 2006..Again, excluding the 1 outlier study eliminated this heterogeneity. CONCLUSIONS: Although prior studies yielded inconsistent conclusions, this analysis strongly supports that higher 6-TGN levels are associated with clinical remission... - An approach to the management of refractory ulcerative colitisI Sonu
University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
Minerva Gastroenterol Dietol 56:213-31. 2010..This review focuses on the management and treatment approaches to refractory UC... - American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel diseaseGary R Lichtenstein
Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
Gastroenterology 130:940-87. 2006 - American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel diseaseGary R Lichtenstein
Hospital of the University of Pennsylvania University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, USA
Gastroenterology 130:935-9. 2006 - Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the questionWojciech Blonski
Gastrointest Endosc 63:493-6. 2006 - Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseasePaul Rutgeerts
Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
Gastrointest Endosc 63:433-42; quiz 464. 2006..There was a numerical trend for patients with better mucosal healing to have a lower rate of Crohn's disease-related hospitalizations... - Infliximab for induction and maintenance therapy for ulcerative colitisPaul Rutgeerts
University Hospital Gasthuisberg, Leuven, Belgium
N Engl J Med 353:2462-76. 2005..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis... - What next after infliximab?Leonard Baidoo
Am J Gastroenterol 100:80-3. 2005..Is this a viable alternative?.. - Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's diseasePaul Rutgeerts
Afdeling Gastroenterologie, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
Gastroenterology 126:402-13. 2004..This analysis of Crohn's disease patients treated with infliximab in ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate clinical practice... - Safety of biologic therapyWojciech Blonski
Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
Inflamm Bowel Dis 13:769-96. 2007..This is because it has been evaluated in many more trials than has any other biologic agent. In addition, postmarketing experience provides very valuable information about adverse events occurring during treatment with this agent... - An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trialDouglas L Seidner
Department of Gastroenterology A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Clin Gastroenterol Hepatol 3:358-69. 2005.... - The effects of infliximab maintenance therapy on health-related quality of lifeBrian G Feagan
Robarts Research Institute, University of Western Ontario, London, Ontario, Canada
Am J Gastroenterol 98:2232-8. 2003..A maintenance regimen of either 5 mg/kg or 10 mg/kg of infliximab is more effective than a single 5-mg/kg infliximab infusion in sustaining this benefit... - Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?Carmen Cuffari
Gastroenterology 124:1988-90. 2003 - Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and updateDavid T Rubin
University of Chicago Medical Center, Chicago, IL 60637, USA
Inflamm Bowel Dis 14:265-74. 2008..This article provides a comprehensive overview of the issues discussed and should act as a guide to shaping the design of future studies in this area... - Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialStephen B Hanauer
Department of Gastroenterology and Nutrition, University of Chicago Medical Center, Chicago, IL 60637, USA
Lancet 359:1541-9. 2002..We did a randomised controlled trial to assess the benefit of maintenance infliximab therapy in patients with active Crohn's disease who respond to a single infusion of infliximab...